SUPPRESSION OF PLASMA ANDROGENS BY THE ANTIANDROGEN FLUTAMIDE IN PROSTATIC CANCER PATIENTS TREATED WITH ZOLADEX, A GnRH ANALOGUE

@article{Ayub1990SUPPRESSIONOP,
  title={SUPPRESSION OF PLASMA ANDROGENS BY THE ANTIANDROGEN FLUTAMIDE IN PROSTATIC CANCER PATIENTS TREATED WITH ZOLADEX, A GnRH ANALOGUE},
  author={Muhammad Rashid Ayub and Michael J. Levell},
  journal={Clinical Endocrinology},
  year={1990},
  volume={32}
}
Chronic treatment with the GnRH (gonadotrophin hormone releasing hormone) agonist Zoladex causes suppression of testicular androgens. Use of antiandrogens has been advocated to block the effects of the initial surge of androgens, and to block any presumed effects of adrenal androgens. We have measured plasma concentrations of androgens and possible precursors before and during treatment in the following prostate cancer patients: 10 who received Zoladex alone (Z), nine who received Zoladex ± the… 
[Suppressive effects of the antiandrogen flutamide on adrenal androgens in advanced prostate cancer patients].
TLDR
It was found that flutamide reduced adrenal androgen levels in prostate cancer patients treated with LH-RH agonist and ACTH suppression might be related to this phenomenon.
A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients
TLDR
Serum adrenal androgen levels decreased significantly in patients treated with a Gn RH antagonist, suggesting that long-term GnRH antagonist treatment may reduce serum adrenalandrogen levels.
Effect of the nonsteroidal antiandrogen nilutamide on adrenal androgen secretion
TLDR
It is concluded that no significant inhibition of adrenal androgen secretion occurs after nilutamide or LHRH agonist treatment, and administration of the antiandrogen alone may partially remove the physiologic decrease in adrenalandrogen secretion observed in the elderly.
Luteinizing hormone (LH)-releasing hormone agonist reduces serum adrenal androgen levels in prostate cancer patients: implications for the effect of LH on the adrenal glands.
TLDR
H receptors in the adrenal cortex cells of the reticular layer might account for the underlying mechanism of reduced adrenal androgens in patients treated with LH-RH agonist with radiotherapy.
Serum testosterone level to predict the efficacy of sequential use of antiandrogens as second-line treatment following androgen deprivation monotherapy in patients with castration-resistant prostate cancer.
TLDR
Serum testosterone could play an important role when delayed maximal androgen blockade is indicated as the second-line treatment in patients with castration-resistant prostate cancer, and might be more beneficial in Patients with a serum testosterone level of ≥ 5ng/dl.
Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions.
TLDR
Preliminary data suggest that nafarelin is equivalent to diethylstilbestrol (stilboestrol) in terms of disease-free survival in men with prostate cancer and as a reliable method of contraception, nAFarelin gives unpredictable results in men and the promising results in women may be offset by hypoestrogenic side effects.
A Randomized Control Trial Comparing the Efficacy of Antiandrogen Monotherapy: Flutamide vs. Bicalutamide
TLDR
Serial changes in prostate-specific antigen, testosterone, dehydroepiandrosterone (DHEA), and androstenedione in patients treated with either of the antiandrogen agents, bicalutamide or flutamide, using a randomized controlled study are compared.
Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer.
TLDR
Flutamide is generally well tolerated and is suitable monotherapy in patients with previously untreated advanced prostatic cancer who wish to preserve sexual potency, however, full assessment of the role of combination androgen blockade awaits publication of the final results of ongoing multicentre trials.
Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.
TLDR
Goserelin is an effective alternative to surgery or estrogen therapy in prostatic cancer palliation, and possibly to ovariectomy in premenopausal breast cancer, and other gynaecological conditions reliant on the pituitary-gonadal axis also appear amenable to hormone manipulation with goserelin.
...
...

References

SHOWING 1-10 OF 62 REFERENCES
Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer.
TLDR
Treatment with an antiandrogen in castrated men inhibit the formation of adrenal androgens due to a blockade at the level of 17, 20-desmolase, and the efficiency of the new combined antihormonal therapy aimed at complete androgen neutralization in prostate cancer is further facilitated.
Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.
TLDR
The use of depot preparation of an LHRH analogue to suppress gonadotrophin and sex hormone secretion offers the convenience of once monthly injections when L HRH analogues are required for the long term treatment of elderly patients with prostatic cancer and children with precocious puberty.
Plasma levels of hydroxy‐flutamide in patients with prostatic cancer receiving the combined hormonal therapy: An LHRH agonist and flutamide
TLDR
It is observed that two to four hours after oral administration of 250 mg of flutamide to healthy young men, as well as to patients with prostate cancer, the plasma concentration of Flu‐OH reaches a peak at approximately 1.7 μM, and it is extremely important to maintain this concentration of the antiandrogen in plasma constant.
Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex).
TLDR
The data clearly demonstrate the considerable therapeutic potential of ICI 118630 in the depot formulation for the treatment of advanced carcinoma of the prostate.
An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
TLDR
The luteinizing hormone releasing hormone, Zoladex, has been used in three centres, Pontefract, Antwerp and Mistelbach, to treat carcinoma of the prostate and reduction of acid phosphatase and subjective and objective tumour responses have been similar to those expected from effective hormonal therapy of prostatic cancer.
New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens
TLDR
The present data show that complete withdrawal of androgens by combined hormonal therapy with the LHRH agonist (or castration) and a pure antiandrogen leads to a positive objective response in more than 95% of cases as opposed to 60%‐70% as reported by many groups using the previous partial hormonal therapy.
Advantages of total androgen blockade in the treatment of advanced prostate cancer.
TLDR
A review of patients in relapse after castration, who are treated with adrenal androgen blockade, indicates that approximately one out of three patients will show an objective remission based on National Prostate Cancer Project (NPCP) criteria.
Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas.
TLDR
It is demonstrated that complete androgen withdrawal consisting of surgical castration in combination with daily treatment with the potent antiandrogen, cyproterone acetate, was no more effective in terms of tumor growth retardation or overall host survival than was partial androgens withdrawal induced by castration alone.
...
...